Artera has developed multimodal AI (MMAI)-enabled predictive and prognostic biomarkers for patients with prostate cancer using large datasets from thousands of patients enrolled in Phase 3 randomized clinical trials4,5.
Related Articles
ArteraAI Achieves SOC 2 Type II Security Compliance Certification
ArteraAI x SOC 2 As part of our commitment to cybersecurity, we are proud to announce that ArteraAI is now SOC 2 Type II cert [...]
ArteraAI Predictive Models
ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. Download the pdf.